Table A3.
Multivariate analysis of association between metabolites in ASNS-catalyzed asparagine synthesis pathway and OS and RFS for all patients using data with complete records of KRAS mutation information (N = 161, females = 78, males = 83).
| Variable a | OS | RFS | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p Value | Int. Sex p Value b | HR | 95% CI | p Value | Int. Sex p Value b | |
| Asparagine | 1.28 | 0.74–2.22 | 0.377 | 0.035 | 2.50 | 1.27–4.91 | 0.008 | 0.010 |
| Aspartate | 1.24 | 0.80–1.93 | 0.345 | 0.967 | 1.59 | 0.96–2.63 | 0.071 | 0.447 |
| Glutamate | 0.68 | 0.26–1.80 | 0.438 | 0.692 | 0.43 | 0.13–1.41 | 0.165 | 0.078 |
| Glutamine | 0.65 | 0.24–1.75 | 0.393 | 0.932 | 0.21 | 0.07–0.63 | 0.005 | 0.716 |
| AMP | 0.74 | 0.47–1.17 | 0.198 | 0.444 | 0.86 | 0.50–1.48 | 0.585 | 0.319 |
| Sex = Male (ref: female) | 2.02 | 0.94–4.32 | 0.070 | - | 0.97 | 0.40–2.34 | 0.947 | - |
| Anatomic location = RCC (ref: LCC) | 0.81 | 0.37–1.78 | 0.598 | - | 0.68 | 0.28–1.70 | 0.415 | - |
| Clinical stage = late (ref: early) | 4.46 | 1.55–12.78 | 0.005 | - | 1.32 | 0.37–4.62 | 0.669 | - |
| Chemotherapy = yes (ref: no) | 1.05 | 0.36–3.10 | 0.924 | 2.58 | 0.67–9.96 | 0.166 | ||
| Age | 1.10 | 1.04–1.16 | <0.001 | - | 0.98 | 0.92–1.05 | 0.604 | - |
| KRAS = mutant (ref: wild type) | 1.09 | 0.50–2.37 | 0.832 | - | 1.48 | 0.60–3.69 | 0.398 | - |
a All of the variables listed were included in one multivariate Cox PH model, where the abundance of each metabolite was treated as a continuous variable and was log2 transformed. b p value of the interaction between the metabolite and sex.